Literature DB >> 9378456

[Mitoxantrone-induced acute left heart failure after intrapleural administration].

H Kahles1, H J Bastian, O Schiffmann, M Geck, F R Helmke, N Golz.   

Abstract

A 79-year-old female was admitted to our hospital because of a malignant pleural effusion following mastectomy 4 years ago. In the patient's history arterial hypertension and previous inferior myocardial infarction have been known. Two doses of 20 mg mitoxantrone were installed intrapleurally at an interval of 4 weeks. Six hours after the second mitoxantrone application and the patient had increasing dyspnea with consecutive left heart failure, pulmonary congestion, and a drop of blood pressure. The white-cell count was 14800/mm3. The levels of creatinine phosphokinase (CPK), lactate dehydrogenase (LDH) and serum aspartate aminotransferase (SGOT) were in the normal range. Transthoracic echocardiography showed concentric left ventricular hypertrophy and a markedly decreased fractional shortening, but no left ventricular dilatation. The electrocardiogram showed newly appeared down-sloping ST-segments and inverted T-waves. Clinical recovery was achieved after 6 days by application of oxygen, dobutamine and furosemide followed by angiotensin converting enzyme inhibition and digitalis. In the echocardiographic control examination 14 days later left ventricular function had normalized. The changes of electrocardiogram normalized 4 weeks later.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9378456     DOI: 10.1007/bf03044581

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  14 in total

Review 1.  Mitoxantrone.

Authors:  T I Poirier
Journal:  Drug Intell Clin Pharm       Date:  1986-02

2.  Comment on mitoxantrone.

Authors:  G DuKart; M J Iatropoulos; A Yacobi
Journal:  Drug Intell Clin Pharm       Date:  1985-03

Review 3.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

4.  Clinical safety and tolerance of mitoxantrone.

Authors:  R J Crossley
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

5.  Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.

Authors:  R S Benjamin; S P Chawla; M S Ewer; C H Carrasco; B Mackay; F Holmes
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

6.  [Efficacy and toxicity of intrapleural mitoxantrone: apropos of 18 cases of pleural metastases of breast cancer].

Authors:  F Feuilhade; B Brun; E Calitchi; Y Otzmeguine; E Haddad; J P Le Bourgeois; B Pierquin
Journal:  Bull Cancer       Date:  1989       Impact factor: 1.276

Review 7.  Mitoxantrone: a new anticancer drug with significant clinical activity.

Authors:  T D Shenkenberg; D D Von Hoff
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

8.  Cardiac evaluation of mitoxantrone.

Authors:  D V Unverferth; B J Unverferth; S P Balcerzak; T A Bashore; J A Neidhart
Journal:  Cancer Treat Rep       Date:  1983-04

9.  Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations.

Authors:  B M Henderson; W J Dougherty; V C James; L P Tilley; J F Noble
Journal:  Cancer Treat Rep       Date:  1982-05

10.  Potential cardiotoxicity with mitoxantrone.

Authors:  F C Schell; H Y Yap; G Blumenschein; M Valdivieso; G Bodey
Journal:  Cancer Treat Rep       Date:  1982-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.